Lantern Pharma Inc. (LTRN) — 10-Q Filings

10-Q Filings (6)

• Lantern Pharma Narrows Q3 Loss Amid R&D Cuts, Cash Up, Equity Down — Nov 12, 2025 Risk: high
  Lantern Pharma Inc. reported a net loss of $4,177,423 for the three months ended September 30, 2025, an improvement from a net loss of $4,505,697 for the same p
• Lantern Pharma Narrows Q2 Loss, R&D Spend Down 22% — Aug 13, 2025 Risk: high
  Lantern Pharma Inc. reported a net loss of $8,867,798 for the six months ended June 30, 2025, an improvement from the $10,400,316 net loss in the same period of
• Lantern Pharma Files 10-Q for Q1 2025 — May 15, 2025 Risk: medium
  Lantern Pharma Inc. filed its 10-Q for the period ending March 31, 2025, reporting on its financial performance and business operations. The company, incorporat
• Lantern Pharma Files Q3 2024 10-Q — Nov 7, 2024 Risk: medium
  Lantern Pharma Inc. filed its 10-Q for the period ending September 30, 2024. The filing covers financial performance and operational updates for the third quart
• Lantern Pharma Files Q2 2024 10-Q — Aug 8, 2024 Risk: medium
  Lantern Pharma Inc. filed its 10-Q for the period ending June 30, 2024. The filing details financial information and business operations for the company, which
• Lantern Pharma Inc. Files 10-Q for Period Ending March 31, 2024 — May 9, 2024 Risk: low
  Lantern Pharma Inc. (LTRN) filed a Quarterly Report (10-Q) with the SEC on May 9, 2024. Lantern Pharma Inc. filed a 10-Q for the quarterly period ended March 31

Popular Companies

AAPL · TSLA · MSFT · AMZN · GOOGL · META · NVDA · JPM · BRK-B · V · JNJ · UNH · XOM · WMT · MA · PG · HD · DIS · BAC · NFLX